Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Conditioned Taste Aversion01:14

Conditioned Taste Aversion

Conditioned taste aversion, also known as sauce béarnaise syndrome, is a phenomenon in which an individual develops an aversion to a certain food taste following a negative experience, typically illness. This form of aversion is a type of classical conditioning in which the taste of the food (conditioned stimulus, CS) is associated with the experience of illness (unconditioned stimulus, UCS).
A notable characteristic of conditioned taste aversion is that it often requires only a single exposure...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Public awareness on histopathology specialty: The doctor behind the microscope.

Indian journal of pathology & microbiology·2026
Same author

Sporotrichoid Violaceous Plaques on the Arm: Answer.

The American Journal of dermatopathology·2026
Same author

Sporotrichoid Violaceous Plaques on the Arm: Challenge.

The American Journal of dermatopathology·2026
Same author

Scar sarcoidosis in burn scars associated with retained surgical staples.

QJM : monthly journal of the Association of Physicians·2026
Same author

Epidemiology of Thyroid Cancer in Jordan Over Two Decades: 2000-2019.

JCO global oncology·2026
Same author

Pleural mesothelioma in a patient with Familial Mediterranean Fever: A case report.

Qatar medical journal·2026

Related Experiment Video

Updated: May 9, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Ibrutinib-induced Sweet syndrome.

Noor Almaani1, Zain Al Ta'ani2, Maram Abdaljaleel3,4

  • 1Department of Dermatology, School of Medicine, University of Jordan, Amman, Jordan. n.almaani@ju.edu.jo.

Naunyn-Schmiedeberg'S Archives of Pharmacology
|May 8, 2026
PubMed
Summary

Ibrutinib, a targeted therapy for chronic lymphocytic leukemia (CLL), can cause Sweet syndrome, a rare skin reaction. Discontinuation of ibrutinib resolved the symptoms, indicating a drug-induced condition.

Keywords:
Drug-induced cutaneous side effectIbrutinibNeutrophilic dermatosis

More Related Videos

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
14:04

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Related Experiment Videos

Last Updated: May 9, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
14:04

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Area of Science:

  • Oncology
  • Dermatology
  • Pharmacology

Background:

  • Ibrutinib is an FDA-approved oral targeted therapy for chronic lymphocytic leukemia (CLL).
  • It functions as an irreversible selective inhibitor of Bruton's tyrosine kinase (Btk).
  • Adverse cutaneous reactions are known side effects of targeted cancer therapies.

Purpose of the Study:

  • To report a case of Sweet syndrome potentially induced by ibrutinib in a CLL patient.
  • To highlight the diagnostic challenges and management of drug-induced dermatological conditions.

Main Methods:

  • A case report of a 54-year-old male patient with CLL treated with ibrutinib.
  • Clinical examination, skin biopsy with histopathological analysis, and medication withdrawal/readministration were employed.
  • Assessment of the temporal relationship between ibrutinib treatment and the onset of skin lesions.

Main Results:

  • The patient developed erythematous, indurated plaques on the face, neck, hands, and scalp 8 months into ibrutinib therapy.
  • Skin biopsy revealed a neutrophil-predominant infiltrate, consistent with Sweet syndrome.
  • Lesions resolved upon ibrutinib withdrawal and topical steroid application, recurring upon readministration.

Conclusions:

  • The findings suggest a strong temporal association between ibrutinib use and the development of Sweet syndrome.
  • Discontinuation of ibrutinib is crucial for managing this adverse cutaneous reaction.
  • This case underscores the importance of considering drug-induced dermatoses in patients receiving targeted therapies.